Paul Mahon Sells 8,300 Shares of United Therapeutics (NASDAQ:UTHR) Stock

United Therapeutics Corporation (NASDAQ:UTHR) EVP Paul Mahon sold 8,300 shares of the firm’s stock in a transaction on Thursday, August 6th. The shares were sold at an average price of $517.05, for a total value of $4,291,515.00. Following the sale, the executive vice president directly owned 45,172 shares in the company, valued at approximately $23,356,182.60. This trade represents a 15.52% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.

United Therapeutics Price Performance

UTHR stock traded up $13.93 during midday trading on Thursday, reaching $532.94. 992,945 shares of the stock were exchanged, compared to its average volume of 490,031. The stock has a market capitalization of $22.62 billion, a PE ratio of 19.67, a P/E/G ratio of 1.73 and a beta of 0.59. United Therapeutics Corporation has a 52 week low of $292.34 and a 52 week high of $609.35. The company has a fifty day moving average price of $540.37 and a 200 day moving average price of $533.71.

United Therapeutics (NASDAQ:UTHR) last posted its earnings results on Wednesday, August 5th. The biotechnology company reported $7.27 EPS for the quarter, beating the consensus estimate of $6.86 by $0.41. United Therapeutics had a return on equity of 19.24% and a net margin of 40.62%.The firm had revenue of $783.30 million during the quarter, compared to the consensus estimate of $804.65 million. During the same period last year, the company earned $6.41 earnings per share. The business’s quarterly revenue was down 1.9% on a year-over-year basis. As a group, analysts anticipate that United Therapeutics Corporation will post 26.65 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of UTHR. Torren Management LLC acquired a new stake in shares of United Therapeutics during the fourth quarter worth $26,000. Activest Wealth Management boosted its position in United Therapeutics by 1,400.0% during the fourth quarter. Activest Wealth Management now owns 60 shares of the biotechnology company’s stock valued at $29,000 after acquiring an additional 56 shares during the last quarter. WealthCollab LLC grew its holdings in United Therapeutics by 55.9% during the 2nd quarter. WealthCollab LLC now owns 106 shares of the biotechnology company’s stock worth $30,000 after acquiring an additional 38 shares during the period. Rakuten Securities Inc. raised its position in shares of United Therapeutics by 76.7% in the 2nd quarter. Rakuten Securities Inc. now owns 106 shares of the biotechnology company’s stock worth $30,000 after acquiring an additional 46 shares in the last quarter. Finally, Entrust Financial LLC acquired a new position in shares of United Therapeutics in the 4th quarter valued at about $31,000. Institutional investors and hedge funds own 94.08% of the company’s stock.

More United Therapeutics News

Here are the key news stories impacting United Therapeutics this week:

• Positive Sentiment: Analyst support remained strong. H.C. Wainwright reiterated its Buy rating and maintained a $660 price target, citing United Therapeutics’ diversified pipeline as a counterbalance to near-term headwinds. Buy Rating Reiterated on United Therapeutics as Diversified Pipeline Offsets Near-Term Headwinds
• Positive Sentiment: Second-quarter EPS beat expectations. United Therapeutics reported earnings of $7.27 per share, above the roughly $6.82–$6.86 analyst consensus and up from $6.41 a year earlier. The company also posted a 40.62% net margin, supporting the stock’s valuation. United Therapeutics Q2 Earnings Surpass Estimates
• Positive Sentiment: Pipeline developments improved the longer-term outlook. Management highlighted regulatory submissions and continued progress for ralinepag and Tyvaso-related programs. Analysts view these products as potential future growth drivers that could diversify the company beyond its existing pulmonary arterial hypertension therapies. United Therapeutics Corporation Reports Second Quarter 2026 Financial Results
• Neutral Sentiment: Royal Bank of Canada lowered its price target from $704 to $677 but retained an Outperform rating, still implying substantial potential upside from recent trading levels. The reduction signals more cautious near-term assumptions rather than a change to the overall bullish view. Benzinga
• Negative Sentiment: Revenue missed estimates and declined year over year. Second-quarter revenue was $783.3 million, below the $804.65 million consensus and down about 2% from the prior year. Competitive pressure and concerns surrounding Tyvaso are the primary near-term operating headwinds. United Therapeutics Q2 Earnings Beat Estimates, Revenues Miss Mark
• Negative Sentiment: CEO Martine Rothblatt sold approximately $4.9 million of stock. The sale reduced her direct holdings by 2.84%, potentially weighing modestly on sentiment, although she continues to own a substantial position. United Therapeutics CEO Stock Sale Filing

Wall Street Analyst Weigh In

UTHR has been the subject of a number of research reports. Morgan Stanley set a $515.00 target price on shares of United Therapeutics in a research report on Thursday. Weiss Ratings cut shares of United Therapeutics from a “buy (b)” rating to a “buy (b-)” rating in a research report on Friday, July 31st. Bank of America dropped their price target on shares of United Therapeutics from $620.00 to $613.00 and set a “neutral” rating for the company in a research note on Friday, July 10th. Royal Bank Of Canada reduced their price objective on shares of United Therapeutics from $704.00 to $677.00 and set an “outperform” rating on the stock in a research note on Thursday. Finally, Raymond James Financial assumed coverage on United Therapeutics in a research report on Friday, April 10th. They set an “outperform” rating and a $700.00 target price for the company. Eleven equities research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company. Based on data from MarketBeat, United Therapeutics currently has a consensus rating of “Moderate Buy” and an average price target of $646.00.

United Therapeutics Company Profile

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.